Omeprazole sulfone
| Title | Journal |
|---|---|
| Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping. | European journal of clinical pharmacology 20120401 |
| Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. | Clinical pharmacology and therapeutics 20120301 |
| Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole. | Drug metabolism and disposition: the biological fate of chemicals 20120101 |
| Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. | The pharmacogenomics journal 20110401 |
| CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole. | Journal of clinical pharmacy and therapeutics 20090801 |
| Effects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMs. | European journal of clinical pharmacology 20080601 |
| Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole. | Acta pharmacologica Sinica 20071001 |
| Validation of chromatographic methods: evaluation of detection and quantification limits in the determination of impurities in omeprazole. | Journal of chromatography. A 20070713 |
| Determination of esomeprazole and its two main metabolites in human, rat and dog plasma by liquid chromatography with tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401 |
| A simple and sensitive bioanalytical assay for simultaneous determination of omeprazole and its three major metabolites in human blood plasma using RP-HPLC after a simple liquid-liquid extraction procedure. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20061205 |
| Determination of omeprazole, hydroxyomeprazole and omeprazole sulfone using automated solid phase extraction and micellar electrokinetic capillary chromatography. | Journal of pharmaceutical and biomedical analysis 20060911 |
| Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4. | European journal of clinical pharmacology 20060801 |
| Use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults. | Journal of clinical pharmacology 20060301 |
| Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. | Clinical pharmacology and therapeutics 20051201 |
| The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. | Clinical pharmacokinetics 20050101 |
| Metabolism of omeprazole after two oral doses in children 1 to 9 months old. | Proceedings of the Western Pharmacology Society 20050101 |
| Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. | Pharmacogenetics 20041201 |
| Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes. | Basic & clinical pharmacology & toxicology 20040901 |
| Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. | Journal of clinical pharmacology 20040601 |
| Assay of omeprazole and omeprazole sulfone by semi-microcolumn liquid chromatography with mixed-function precolumn. | Journal of chromatography. B, Biomedical sciences and applications 20010425 |
| Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. | The Journal of pharmacology and experimental therapeutics 19940401 |